Surprisingly, we demonstrate that GPR44/DP2 antagonism do not acutely improve insulin secretion in T2DM patients irrespective of the endogenous incretin response, i. e. neither during MMTT nor GGI. This evidence concerns the gene PTGDR2 and type 2 diabetes mellitus.